1. Home
  2. UTHR vs ALAB Comparison

UTHR vs ALAB Comparison

Compare UTHR & ALAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • ALAB
  • Stock Information
  • Founded
  • UTHR 1996
  • ALAB 2017
  • Country
  • UTHR United States
  • ALAB United States
  • Employees
  • UTHR N/A
  • ALAB N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • ALAB
  • Sector
  • UTHR Health Care
  • ALAB
  • Exchange
  • UTHR Nasdaq
  • ALAB NYSE
  • Market Cap
  • UTHR 13.4B
  • ALAB 15.0B
  • IPO Year
  • UTHR 1999
  • ALAB 2024
  • Fundamental
  • Price
  • UTHR $294.28
  • ALAB $131.10
  • Analyst Decision
  • UTHR Buy
  • ALAB Strong Buy
  • Analyst Count
  • UTHR 13
  • ALAB 15
  • Target Price
  • UTHR $379.69
  • ALAB $104.71
  • AVG Volume (30 Days)
  • UTHR 547.4K
  • ALAB 5.7M
  • Earning Date
  • UTHR 07-30-2025
  • ALAB 08-05-2025
  • Dividend Yield
  • UTHR N/A
  • ALAB N/A
  • EPS Growth
  • UTHR 17.94
  • ALAB N/A
  • EPS
  • UTHR 25.63
  • ALAB 0.26
  • Revenue
  • UTHR $3,077,800,000.00
  • ALAB $490,474,000.00
  • Revenue This Year
  • UTHR $14.37
  • ALAB $80.73
  • Revenue Next Year
  • UTHR $6.59
  • ALAB $28.94
  • P/E Ratio
  • UTHR $11.48
  • ALAB $522.32
  • Revenue Growth
  • UTHR 17.62
  • ALAB 200.19
  • 52 Week Low
  • UTHR $266.98
  • ALAB $36.22
  • 52 Week High
  • UTHR $417.82
  • ALAB $147.39
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 49.57
  • ALAB N/A
  • Support Level
  • UTHR $272.12
  • ALAB N/A
  • Resistance Level
  • UTHR $307.71
  • ALAB N/A
  • Average True Range (ATR)
  • UTHR 8.47
  • ALAB 0.00
  • MACD
  • UTHR -1.25
  • ALAB 0.00
  • Stochastic Oscillator
  • UTHR 62.26
  • ALAB 0.00

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About ALAB ASTERA LABS INC

Astera Labs Inc designs and delivers semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform integrates semiconductor technology, microcontrollers, sensors, and software to enhance performance, scalability, and data management. The company offers products such as integrated circuits (ICs), boards, and modules, catering to hyperscalers and system OEMs. The company's solutions focus on data, network, and memory management in AI-driven platforms.

Share on Social Networks: